ANEB צמיחת רווחי EPS רבעונית Anebulo

Anebulo Pharmaceuticals (ANEB) develops antidotes for emergency THC intoxication relief, targeting the B2B medical segment. Quarterly earnings per share growth reflects current dynamics, with the value holding at 46.40. The absence of competitors in this niche promises stable patent income; however, the company is currently in the clinical trial stage and does not yet generate operating cash flow.
פילוחי מדדים פיננסיים ומדדי שוק עבור Anebulo Pharmaceuticals, Inc. (ANEB)

For Anebulo Pharmaceuticals (ANEB), which operates in the defensive addiction therapy sector, the quarterly growth rate of net income per share reflects the efficiency of drug commercialization regardless of GDP dynamics. This metric measures the percentage change in EPS between reporting periods, allowing investors to assess the business's resilience to regulatory shocks and the pace of capitalization following successful clinical phases.